NCT02760849 - Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations | Biotech Hunter

Enrollment

374

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

May 31, 2041

Study Completion Date

May 31, 2041

Conditions

Deleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationDeleterious BRIP1 Gene MutationDeleterious EPCAM Gene MutationDeleterious MLH1 Gene MutationDeleterious MSH2 Gene MutationDeleterious MSH6 Gene MutationDeleterious PALB2 Gene MutationDeleterious PMS2 Gene MutationDeleterious RAD51C Gene MutationDeleterious RAD51D Gene MutationHereditary Breast and Ovarian Cancer SyndromePremenopausal

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Oophorectomy

Undergo ISDO

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Salpingectomy

Undergo ISDO

PROCEDURE

Salpingo-Oophorectomy

Undergo RRSO

Trial Locations (9)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

55905

Mayo Clinic, Rochester

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Siteman Cancer Center at Washington University, St Louis

77030

M D Anderson Cancer Center, Houston

98195

University of Washington Medical Center, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER